NephroGenex Inc

NephroGenex — Investor Presentation (July 2016)

10 slides from NephroGenex's investor presentation, Jul 6, 2016

  1. Slide 1: Supplemental Corporate Presentation July 2016

    Supplemental Corporate Presentation July 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward- looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expe

  3. Slide 3: Overview of Phase 3 Study - PIONEER 3

    Objective:  Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population:  Type 2 diabetic subjects  Baseline SCr >1.3 and <3.0 mg/dL (eGFR > 20 ml/min)  Protein/creat

  4. Slide 4: Phase 3 Progress

    4 Phase 3 Progress  As of April 30, 2016, 328 patients (out of 600) were enrolled during the first of two phase 3 trials required for approval (total of 1,200 patients)  The study successfully passed three DSMB reviews (2/21/2015; 7/29/2015; 1/21/2016)  The study was halted due to financial consi

  5. Slide 5: Phase 3 Data – Change from Baseline in SCr (Unblinded Data From Terminated Phase 3 Trial – PYR-311)

    5 Phase 3 Data – Change from Baseline in SCr (Unblinded Data From Terminated Phase 3 Trial – PYR-311 ) P 300mg bd P 300mg bd P 300mg bd S C r m g/ dL + S E ( C hange fr om B aseline ) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 n= 92 n=94 n= 55 n=50 n= 23 n=21 6 months 9 months 12 months All randomized subjects P=0

  6. Slide 6: Phase 3 Data – Change from Baseline in SCr by Baseline SCr

    Phase 3 Data – Change from Baseline in SCr by Baseline SCr (SCr < 2mg/dL vs >2mg/dL at 6 Months) 6 P 300mg bd P 300mg bd S C r m g/ dL + S E ( C hange fr om B aseline ) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 P=0.164 P=0.647 n= 40 n=38 n= 52 n=56 Baseline SCr <2mg/dL Baseline SCr >2mg/dL All randomized subjects

  7. Slide 7: Phase 3 Data - Slope Analysis: Pyridorin vs Placebo

    Phase 3 Data - Slope Analysis: Pyridorin vs Placebo 7 Baseline to Month 9 Baseline to Month 12 Month 3 to Month 12 Estimate (SE) -0.0010 (0.00218) -0.0002 (0.00182) -0.0004 (0.00215) 95% CI (-0.0053, 0.0032) (-0.0037, 0.0034) (-0.0046, 0.0038) P-value 0.6314 0.9272 0.8522

  8. Slide 8: Phase 2b & Phase 3 Data: Historical Comparison at 6 months

    Phase 2b & 3 Data: Historical Comparison at 6 months 8 PYR 311 at 26 weeks (Terminated Phase 3 Study) NS, P=0.27 n=92 n=94

  9. Slide 9: Phase 2b & Phase 3 Data: Historical Comparison at 12 months

    Phase 2b & 3 Data: Historical Comparison at 12 months 9 PYR-210 (Phase 2b – Month 12) PYR-311 (Terminated phase 3 – Month 12) P=0.57 n=23 n=21

  10. Slide 10: Phase 3 Safety Data Summary

    Phase 3 – Safety Data Summary Phase 3 study was actively monitored by a Data Safety Monitoring Board and no safety issues were highlighted. At the time of study termination, three reviews had been undertaken with recommendations to continue the study as planned at each review (2/21/2015; 7/29/2015;

NephroGenex — Investor Presentation (July 2016) on 6ix